Taft Pharmaceutical & Life Sciences attorneys Steve Auten and Jaimin Shah contributed to Evidence in Patent Cases, published by Bloomberg BNA in 2019. Auten was co-editor of the reference book, which explains the use of evidence as it relates specifically to issues encountered in patent litigation from case initiation through appeal. Divided into two distinct sections, the authors share insight, analysis, practice notes and case citations. Auten, Shah and summer associate Courtney Carapella penned Chapter 12 “Hatch-Waxman Cases” which discusses inherency in Hatch-Waxman cases examined from both anticipation and obviousness perspectives.

Auten is a widely recognized and seasoned attorney in Hatch-Waxman and biosimilar matters, including related patent litigation, and is followed by key industry leaders (brand and generic alike), law firms, analysts, educators and others on his LinkedIn blog “Hatch Waxman ANDA Litigation Forum,” which has more than 8,800 members worldwide. He currently represents clients primarily in the areas of Paragraph IV design strategies, Hatch-Waxman litigation and biosimilar market opportunities.

Shah focuses on patent litigation and counseling related to pharmaceuticals and biosimilars, as well as software-related patent litigation and inter partes review. He has represented world-class pharmaceutical companies in various phases of patent litigation and has extensive experience working with experts to develop scientific non-infringement and/or invalidity defenses, and drafting related reports.